525 related articles for article (PubMed ID: 33879893)
41. [
Gui J; Li M; Xu J; Zhang X; Mei H; Lan X
Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2308-2319. PubMed ID: 38467921
[TBL] [Abstract][Full Text] [Related]
42. Prognostic role of baseline
Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
[TBL] [Abstract][Full Text] [Related]
43. Metabolic tumor volume derived from
Ding C; Mao X; Li N; Huang M; Huang Z; Bao W; Li H; Fan J
Hell J Nucl Med; 2022; 25(1):63-70. PubMed ID: 35503557
[TBL] [Abstract][Full Text] [Related]
44. Nucleophosmin 1 overexpression correlates with
Zhou LM; Yuan LL; Gao Y; Liu XS; Dai Q; Yang JW; Pei ZJ
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):904-912. PubMed ID: 32856112
[TBL] [Abstract][Full Text] [Related]
45. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
[TBL] [Abstract][Full Text] [Related]
46. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
47. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
48. The prognostic value of volume-based parameters using
Park JS; Lee N; Beom SH; Kim HS; Lee CK; Rha SY; Chung HC; Yun M; Cho A; Jung M
Gastric Cancer; 2018 Mar; 21(2):213-224. PubMed ID: 28643145
[TBL] [Abstract][Full Text] [Related]
49. Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Surgically Treated Stage I Lung Adenocarcinoma Patients.
Tosi D; Pieropan S; Cattoni M; Bonitta G; Franzi S; Mendogni P; Imperatori A; Rotolo N; Castellani M; Cuzzocrea M; Schiorlin I; Casagrande S; De Palma D; Nosotti M; Dominioni L
Clin Nucl Med; 2021 Aug; 46(8):621-626. PubMed ID: 34034316
[TBL] [Abstract][Full Text] [Related]
50. [Prognostic value of (18)F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) in extensive-stage small cell lung cancer].
Ding CY; Guo Z; Li YY; Li TR
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):828-834. PubMed ID: 29151289
[No Abstract] [Full Text] [Related]
51. Baseline [
Yang Q; Luo Y; Zhang Y; Zhang W; Zhou D; Li F
Eur Radiol; 2022 Aug; 32(8):5568-5576. PubMed ID: 35316362
[TBL] [Abstract][Full Text] [Related]
52. Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.
Sjöholm T; Korenyushkin A; Gammelgård G; Sarén T; Lövgren T; Loskog A; Essand M; Kullberg J; Enblad G; Ahlström H
Cancer Imaging; 2022 Dec; 22(1):76. PubMed ID: 36575477
[TBL] [Abstract][Full Text] [Related]
53. Texture analysis of
Nakajo M; Jinguji M; Nakabeppu Y; Nakajo M; Higashi R; Fukukura Y; Sasaki K; Uchikado Y; Natsugoe S; Yoshiura T
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):206-214. PubMed ID: 27613542
[TBL] [Abstract][Full Text] [Related]
54. Incorporating radiomic feature of pretreatment 18F-FDG PET improves survival stratification in patients with EGFR-mutated lung adenocarcinoma.
Chen YH; Wang TF; Chu SC; Lin CB; Wang LY; Lue KH; Liu SH; Chan SC
PLoS One; 2020; 15(12):e0244502. PubMed ID: 33370365
[TBL] [Abstract][Full Text] [Related]
55. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y; Onishi H; Nambu A; Araki T
Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
[TBL] [Abstract][Full Text] [Related]
56. The value of dynamic FDG PET/CT in the differential diagnosis of lung cancer and predicting EGFR mutations.
Wumener X; Zhang Y; Zang Z; Du F; Ye X; Zhang M; Liu M; Zhao J; Sun T; Liang Y
BMC Pulm Med; 2024 May; 24(1):227. PubMed ID: 38730287
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of Amide Proton Transfer-Weighted Imaging for Lung Cancer Subtype and Epidermal Growth Factor Receptor: A Comparative Study With Diffusion and Metabolic Parameters.
Meng N; Fu F; Feng P; Li Z; Gao H; Wu Y; Zhang J; Wei W; Yuan J; Yang Y; Liu H; Cheng J; Wang M
J Magn Reson Imaging; 2022 Oct; 56(4):1118-1129. PubMed ID: 35258145
[TBL] [Abstract][Full Text] [Related]
58. The role of pre-treatment and mid-treatment 18F-FDG PET/CT imaging in evaluating prognosis of peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS).
Zhang Y; Wang G; Zhao X; Hu Y; Tan Su Yin E; Chen D; Wang H; Zhao K
BMC Med Imaging; 2021 Oct; 21(1):145. PubMed ID: 34627196
[TBL] [Abstract][Full Text] [Related]
59. Baseline Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured on 18F-FDG PET-CT Predict Outcomes in T-Cell Lymphoblastic Lymphoma.
Feng X; Wen X; Li L; Sun Z; Li X; Zhang L; Wu J; Fu X; Wang X; Yu H; Ma X; Zhang X; Xie X; Han X; Zhang M
Cancer Res Treat; 2021 Jul; 53(3):837-846. PubMed ID: 33285054
[TBL] [Abstract][Full Text] [Related]
60. Correlation between combining
Ruan M; Liu L; Wang L; Lei B; Sun X; Chang C; Shen Y; Xie W
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1183-1197. PubMed ID: 31897590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]